Document is current

Any future updates will be listed below

NSCLC: Neue Option zur Erstlinientherapie bei ALK-Positivität

Crossref DOI link: https://doi.org/10.1007/s15015-018-4011-1

Published Online: 2018-05-02

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark